Additionally, studies performed in an experimental model of hypertension and diabetes have shown that treatment with the angiotensin II antagonist irbesartan prevented the development of albuminuria and the down-regulation of nephrin expression, without a prominent influence on blood pressure levels [15]. This evidence concerns the gene AGT and diabetes mellitus.